Please login to the form below

Not currently logged in
Email:
Password:

Astellas withdraws drug application in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan, the first market in which it had filed the drug.

The marketing application, which was submitted in late September 2010, had been seeking approval of the oral Factor Xa direct inhibitor for the prevention of venous thromboembolism (VTE) in patients at risk, such as those undergoing orthopaedic surgical procedures in the lower limbs.

Astellas said it was withdrawing the application based on feedback from Japanese regulators that additional clinical trials would be required before the drug could be approved. The marketing application contained two phase II/III studies that compared darexaban to placebo in patients who had elective total knee or hip replacement surgeries in Japan and other Asian countries.

In addition, a North American phase II study for VTE prevention in patients after elective primary knee arthroplasty demonstrated dose-dependent efficacy in VTE prevention, according to the company.

Astellas said it will seek a partner for the development and commercialisation of darexaban for the VTE indication in the US and Europe and for an indication of stroke prevention in atrial fibrillation globally. "Astellas expects to decide future plans, including the indication of VTE in Japan, based on the outcome of the partnership discussion," the company noted.

Darexaban, which was discovered and developed by Astellas, works by directly and selectively inhibiting activated Factor X in the cascade of blood coagulation.

16th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...